Related Experiment Video
Updated: Aug 8, 2026
Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
Published on: March 7, 2022
PDCD4/PPARα axis regulates oxidative stress-mediated microvascular endothelial injury in myocardial
Midilibieke Hasidaer1, Yuchun Yang1, Zhen Bao2
1Department of General Cardiology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Abstract:
Cardiac microvascular endothelial cell (CMEC) injury is a primary driver of microvascular obstruction and the no-reflow phenomenon during myocardial ischemia/reperfusion (I/R). While Programmed Cell Death 4 (PDCD4) is known to exacerbate cardiovascular diseases, its precise role and regulatory mechanisms in CMEC barrier dysfunction and inflammatory adhesion during I/R remain unclear. In this study, we demonstrate that PDCD4 deletion significantly mitigates I/R-induced cardiac dysfunction, reduces infarct size, and preserves microvascular ultrastructure in mice. In vitro experiments using a hypoxia/reoxygenation (H/R) model revealed that PDCD4 knockdown preserves CMEC viability, suppresses apoptosis, and maintains endothelial barrier integrity by restoring tight junction proteins (ZO-1, Claudin-1, and Occludin). Furthermore, PDCD4 inhibition significantly reduced pathological permeability and attenuated the adhesion of neutrophils and macrophages by downregulating ICAM-1. Mechanistically, PDCD4 directly interacts with Peroxisome Proliferator-Activated Receptor alpha (PPARα) at the protein level and restricts its protective antioxidant function. Co-immunoprecipitation and immunofluorescence supported this interaction. Silencing PDCD4 restored PPARα-dependent antioxidant responses, leading to a marked reduction in oxidative stress (decreased ROS and MDA, increased SOD). Crucially, double-knockdown rescue experiments confirmed that the protective effects of PDCD4 depletion against H/R-induced apoptosis, barrier disruption, and inflammatory adhesion were largely abolished upon concurrent PPARα silencing. These findings establish that PDCD4 exacerbates I/R-induced CMEC injury by binding to and inhibiting PPARα-mediated antioxidant homeostasis. Targeting the PDCD4-PPARα interaction axis presents a promising therapeutic strategy to prevent microvascular dysfunction and improve outcomes following acute myocardial infarction.
Insights
Programmed Cell Death 4 (PDCD4) worsens heart microvascular injury after ischemia/reperfusion (I/R). Inhibiting PDCD4 protects cardiac microvascular endothelial cells (CMECs) by restoring antioxidant function via PPARα, improving outcomes.
Area of Science:
- Cardiovascular Biology
- Cellular and Molecular Medicine
- Pathophysiology
Background:
- Cardiac microvascular endothelial cell (CMEC) injury drives microvascular obstruction and no-reflow after myocardial ischemia/reperfusion (I/R).
- Programmed Cell Death 4 (PDCD4) is implicated in cardiovascular diseases, but its role in CMEC dysfunction during I/R is unknown.
Purpose of the Study:
- To elucidate the role of PDCD4 in CMEC injury during I/R.
- To investigate the underlying mechanisms, particularly the interaction with Peroxisome Proliferator-Activated Receptor alpha (PPARα).
Main Methods:
- Utilized mouse models of I/R and in vitro hypoxia/reoxygenation (H/R) models of CMECs.
- Employed gene knockdown, co-immunoprecipitation, immunofluorescence, and assessment of endothelial barrier integrity, apoptosis, oxidative stress markers, and inflammatory cell adhesion.
Main Results:
- PDCD4 deletion mitigated I/R-induced cardiac dysfunction and infarct size.
- PDCD4 knockdown preserved CMEC viability, reduced apoptosis, maintained barrier integrity, and decreased inflammatory cell adhesion.
- PDCD4 directly inhibits PPARα's antioxidant function; PDCD4 silencing restored PPARα-mediated antioxidant responses.
Conclusions:
- PDCD4 exacerbates I/R-induced CMEC injury by inhibiting PPARα-mediated antioxidant homeostasis.
- Targeting the PDCD4-PPARα interaction is a potential therapeutic strategy for myocardial infarction.
